IDYA
Price
$37.05
Change
+$1.96 (+5.59%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
3.08B
75 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$41.58
Change
+$1.22 (+3.02%)
Updated
Jan 14 closing price
Capitalization
3.21B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs XENE

Header iconIDYA vs XENE Comparison
Open Charts IDYA vs XENEBanner chart's image
IDEAYA Biosciences
Price$37.05
Change+$1.96 (+5.59%)
Volume$19.35K
Capitalization3.08B
Xenon Pharmaceuticals
Price$41.58
Change+$1.22 (+3.02%)
Volume$1.2M
Capitalization3.21B
IDYA vs XENE Comparison Chart in %
View a ticker or compare two or three
VS
IDYA vs. XENE commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (IDYA: $37.03 vs. XENE: $41.58)
Brand notoriety: IDYA and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 164% vs. XENE: 137%
Market capitalization -- IDYA: $3.25B vs. XENE: $3.21B
IDYA [@Biotechnology] is valued at $3.25B. XENE’s [@Biotechnology] market capitalization is $3.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, both IDYA and XENE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than XENE.

Price Growth

IDYA (@Biotechnology) experienced а -2.19% price change this week, while XENE (@Biotechnology) price change was -1.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

XENE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.21B) and IDYA($3.08B) have the same market capitalization . IDYA YTD gains are higher at: 1.504 vs. XENE (-7.229). IDYA has higher annual earnings (EBITDA): -204.84M vs. XENE (-338.18M). IDYA has more cash in the bank: 787M vs. XENE (462M). XENE has less debt than IDYA: XENE (8.33M) vs IDYA (27.2M). IDYA has higher revenues than XENE: IDYA (215M) vs XENE (7.5M).
IDYAXENEIDYA / XENE
Capitalization3.08B3.21B96%
EBITDA-204.84M-338.18M61%
Gain YTD1.504-7.229-21%
P/E RatioN/AN/A-
Revenue215M7.5M2,867%
Total Cash787M462M170%
Total Debt27.2M8.33M327%
FUNDAMENTALS RATINGS
IDYA vs XENE: Fundamental Ratings
IDYA
XENE
OUTLOOK RATING
1..100
1769
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
76
Overvalued
PROFIT vs RISK RATING
1..100
6037
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
3853
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (26) in the null industry is somewhat better than the same rating for XENE (76) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as IDYA (60) in the null industry. This means that XENE’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as XENE (97) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XENE’s over the last 12 months.

IDYA's Price Growth Rating (38) in the null industry is in the same range as XENE (53) in the Biotechnology industry. This means that IDYA’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that XENE’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 24 days ago
71%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBHCX15.910.09
+0.57%
Neuberger Equity Income C
MINIX49.310.09
+0.18%
MFS International Intrinsic Value I
DCDGX13.28-0.03
-0.23%
Dunham Small Cap Growth C
AUUCX21.01-0.10
-0.47%
AB Select US Equity C
NINDX54.69-0.29
-0.53%
Columbia Large Cap Index Inst

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-4.75%
NUVL - IDYA
59%
Loosely correlated
+2.03%
XNCR - IDYA
58%
Loosely correlated
-1.62%
XENE - IDYA
57%
Loosely correlated
-2.11%
DYN - IDYA
55%
Loosely correlated
-2.41%
IMTX - IDYA
54%
Loosely correlated
+2.40%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+3.02%
IDYA - XENE
57%
Loosely correlated
+5.53%
NUVL - XENE
57%
Loosely correlated
+6.59%
SGMO - XENE
53%
Loosely correlated
-3.43%
XNCR - XENE
52%
Loosely correlated
+3.66%
NRIX - XENE
51%
Loosely correlated
+0.58%
More